Niaspan
Sponsors
University of Oxford, Cedars-Sinai Medical Center, Organon and Co, Baylor College of Medicine, GlaxoSmithKline
Conditions
AtherosclerosisCardiovascular OutcomesCoronary Artery DiseaseDyslipidaemiasDyslipidemiaDyslipidemiasHealthyHypercholesterolemia
Phase 1
Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)
CompletedNCT00652431
Start: 2007-05-31End: 2007-07-31Updated: 2022-02-16
Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)
CompletedNCT01071291
Start: 2010-02-28End: 2010-09-30Updated: 2015-10-12
A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)
CompletedNCT01104519
Start: 2008-03-31End: 2008-07-31Updated: 2015-07-30
Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
CompletedNCT01809301
Start: 2013-03-31End: 2013-05-31Updated: 2013-08-22
Phase 2
Phase 3
Phase 4
Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women
CompletedNCT00590629
Start: 2002-06-30End: 2005-11-30Updated: 2011-09-14
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
CompletedNCT00687076
Start: 2004-04-30End: 2010-12-31Updated: 2020-02-06
Benefit of Elevation of HDL-C in Women
CompletedNCT01921010
Start: 2003-06-30End: 2005-06-30Updated: 2019-04-23